These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31685562)

  • 21. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival.
    Xing S; Zheng X; Zeng T; Zeng MS; Zhong Q; Cao YS; Pan KL; Wei C; Hou F; Liu WL
    World J Gastroenterol; 2017 Nov; 23(43):7693-7704. PubMed ID: 29209110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.
    Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
    Mediators Inflamm; 2017; 2017():9538451. PubMed ID: 28932021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts.
    Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P
    Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
    Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
    Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population.
    Allin KH; Bojesen SE; Johansen JS; Nordestgaard BG
    Br J Cancer; 2012 Jan; 106(1):199-205. PubMed ID: 22095223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
    Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
    Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
    Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
    Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study.
    Conrozier T; Carlier MC; Mathieu P; Colson F; Debard AL; Richard S; Favret H; Bienvenu J; Vignon E
    Ann Rheum Dis; 2000 Oct; 59(10):828-31. PubMed ID: 11005786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.
    Murakawa M; Yamamoto N; Kamioka Y; Kamiya M; Kobayashi S; Ueno M; Morimoto M; Atsumi Y; Aoyama T; Tamagawa H; Yukawa N; Rino Y; Masuda M; Morinaga S
    In Vivo; 2020; 34(1):347-353. PubMed ID: 31882498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.
    Liu X; Zhang Y; Zhu Z; Ha M; Wang Y
    Med Oncol; 2014 Aug; 31(8):85. PubMed ID: 24996799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
    Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
    Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40.
    Ataseven A; Kesli R
    G Ital Dermatol Venereol; 2016 Jun; 151(3):244-50. PubMed ID: 25279492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
    Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
    Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients.
    Höbaus C; Tscharre M; Herz CT; Pesau G; Wrba T; Koppensteiner R; Schernthaner GH
    Atherosclerosis; 2018 Jul; 274():152-156. PubMed ID: 29783062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.